Haas Jason
CIK 0001883821
Chief Financial OfficerDirector
Filings
13
Latest May 11, 2026
Issuers covered
3
Showing
13 of 13
Page 1
Track record
4 of 5 open-market trades scored (80% price coverage) - 1 issuer without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 4 | 75% | +16.4% | +22.6% | +25.5% | -5.1% |
| 90 days | 4 | 25% | -63.1% | -84.4% | +1.3% | -84.8% |
| 180 days | 4 | 25% | -48.8% | -92.7% | +84.8% | -94.3% |
| 365 days | 4 | 25% | -50.0% | -99.9% | +99.6% | -99.9% |
Issuers
Companies where Haas Jason has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals, Inc. | 8 | Nov 20, 2024 |
| LGND | Ligand Pharmaceuticals Inc | 4 | Jun 10, 2025 |
| ODTX | Odyssey Therapeutics, Inc. | 1 | May 11, 2026 |
All filings
13 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|